CVS Group plc has been reporting weekly share repurchases since its full-year results of 24 September, when it announced a further £50m programme after finishing a £20m buyback. Its latest filing, a total voting rights notice, came on 30 October.

What happened

CVS, which trades under the ticker LSE:CVSG, is a veterinary services group and a constituent of the FTSE All-Share index. There is no fresh trading update. The most recent items on are total voting rights on 30 October, transactions in own shares on 26 and 19 October, and the posting of the Annual Report and notice of annual meeting on 23 October.

The figures that follow come from an available data of the results for the year ended 30 June 2026, not from the full announcement, and they have not been independently checked. (LSE:CVSG)

Revenue rose 5.9% to £712.8m, with like-for-like sales growth of 2.1%. Adjusted EBITDA reached £141.5m, a Margin of 19.9%, and adjusted Earnings Per Share rose 6.9% to 85.6p. The final Dividend was 9.0p a share, with confirmation of Dividend Dates flagged in a 30 September filing.

Why it matters for investors

The gap between reported and adjusted numbers stands out. Profit before tax was £32.0m, held back by higher Depreciation and notable costs, against adjusted EBITDA several times larger. Investors assessing the buyback may want to look through to cash generation, as adjusted measures exclude items that are real costs. That perspective is our analysis.

The difference between 5.9% total Revenue growth and 2.1% like-for-like growth also shows how much of the increase depended on factors other than existing sites, which would include acquisitions and expansion. Australia produced £79.1m of revenue, described as significant expansion. The summary did not give figures for the UK segment.

Capital returns have stepped up alongside this. A company completing £20m and starting £50m is signalling that it sees repurchases as a good use of cash, even with its overseas expansion continuing. The summary did not state the timing of the larger programme.

The Balance Sheet has also been addressed, with the group refinancing its £350m Loan facilities. Net Debt and Leverage were not stated in the summary, so the capacity to fund the programme cannot be judged from it alone. Readers should check the full results or annual report.

Regulatory backdrop

Veterinary services in the UK have been an area of competition scrutiny, but the summary reviewed contained no comment on any regulatory matter. No statement about its current status is made here, and readers should consult the annual report posted on 23 October for the company's own account.

Outlook language was limited to a general reference to confidence in long-term prospects.

How the shares have performed

Hargreaves Lansdown's delayed FTSE All-Share (LSE:CVSG) table, viewed on 3 November without a timestamp, showed CVS at 1,367.00p, up 7.00p or 0.51% on the day. On that price, and on our calculation, the shares trade at about 16 times the 85.6p adjusted earnings per share reported for the last financial year. The multiple rests on adjusted earnings and would be much higher on statutory profit.

The 9.0p final dividend represents a Yield of about 0.7% at the same price. For this group, Capital return therefore leans more on repurchases than on dividends, in our view.

What to watch next

The annual meeting is the next scheduled event, with notice posted on 23 October; the date itself was not in the pages reviewed. Trading comments at that meeting could provide the first numbers on the current year.

Investors can follow the pace of the buyback through the regular transaction notices, and monthly total voting rights filings show the running effect on share count. They may also watch whether like-for-like growth improves from 2.1%, and how quickly Australian revenue builds on the £79.1m base. A PDMR dealing was filed on the results day, but that notice was not opened for this article.